MK-677 for muscle gains: what the evidence actually shows
Quick answer
MK-677 (ibutamoren) is an orally bioavailable ghrelin receptor agonist that stimulates GH and IGF-1 secretion. Clinical studies have documented improvements in REM sleep architecture and appetite stimulation as primary pharmacodynamic effects. Chronic use raises IGF-1, which warrants baseline and follow-up lab monitoring, particularly for fasting glucose and insulin sensitivity, neither of which this creator discusses.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @liftsbyfahd actually say?
The creator is starting a four-week, 15 mg daily cycle of MK-677 and plans to document it. His main hopes are better recovery and deeper sleep. His main worries are water retention and a bigger appetite. He says he's taking it at night because it will "help to sleep" and reduce daytime hunger. He also mentions "no longer being natty" as of today.
A few things stand out immediately. He mispronounces it as "MK67" and references "girl comorant," which appears to be a mangled attempt at saying "ghrelin" or possibly a reference to growth hormone release. These aren't just verbal slips. They suggest a limited understanding of the mechanism he's experimenting with. That matters when you're talking about a compound that affects your endocrine system.
Does the science back this up?
On sleep and recovery, he's actually closer to correct than most MK-677 influencers. That's worth acknowledging. MK-677 (ibutamoren) is a ghrelin receptor agonist and growth hormone secretagogue. It raises GH and IGF-1 levels by mimicking ghrelin. On the sleep side, Copinschi et al. (1997, American Journal of Physiology) found that MK-677 increased REM sleep duration and sleep quality in healthy older adults. More recently, Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) confirmed increases in GH pulse amplitude with oral dosing.
On appetite, the science is straightforward and the creator is right to be nervous. Ghrelin is the hunger hormone. Activating its receptor reliably increases appetite in clinical settings. van der Lely et al. (2004, Endocrine Reviews) documented significant appetite stimulation as one of the most consistent effects of ghrelin-pathway activation. Taking it at night to blunt daytime hunger is a common user strategy, but there's no controlled evidence that timing meaningfully reduces total caloric drive versus simply shifting when it peaks.
What did they get wrong (or right)?
Right: The sleep improvement rationale is scientifically grounded. The appetite concern is well-founded and honest. The water retention worry is also accurate. MK-677 increases aldosterone-like fluid retention in some users, and this is documented in clinical trials, not just gym lore.
Wrong: The "girl comorant" reference is almost certainly a garbled attempt at describing ghrelin or growth hormone-releasing hormone, neither of which he explains correctly. More importantly, he frames this as a simple four-week experiment with no mention of baseline bloodwork, no mention of monitoring IGF-1 levels, and no mention of a prescribing provider. MK-677 chronically elevates IGF-1. Hartman et al. (2001, Journal of Clinical Endocrinology and Metabolism) noted that sustained IGF-1 elevation raises questions about long-term safety signals including insulin resistance, which he doesn't address at all. His blood sugar isn't discussed once. That's a gap.
Also worth flagging: calling a four-week run a "short cycle" undersells the fact that MK-677's half-life means you can hit steady-state IGF-1 elevation within days. Four weeks is not trivial from an endocrine standpoint.
What should you actually know?
MK-677 is not a SARM, though it's often sold alongside them. It is an orally active ghrelin receptor agonist. It is not FDA-approved for any indication. It is not legal to sell as a dietary supplement in the U.S. It is available through some compounding pharmacies under physician oversight for specific clinical applications, but self-sourcing from the gray market, which is what this video implies, comes with real quality control risks.
The sleep and recovery benefits the creator is chasing are real enough in the literature to take seriously. But the studies showing those benefits were conducted in controlled settings with verified compounds, baseline bloodwork, and medical supervision. Training six to seven days a week and layering in a compound that elevates IGF-1 and affects insulin sensitivity without any metabolic monitoring is a risk that doesn't appear anywhere in this video.
If you're genuinely interested in whether MK-677 could be appropriate for your recovery goals, that conversation belongs with a licensed provider who can look at your actual labs, not a TikTok day-one vlog.
Bottom line on the claims
The creator gets partial credit for identifying real effects of MK-677: sleep quality improvement and appetite stimulation are documented. The night-dosing strategy is plausible but unproven in controlled trials. What's missing is everything about safety monitoring, IGF-1 tracking, blood glucose, sourcing quality, and the fact that in most jurisdictions you need a prescription to obtain this compound legally through regulated channels. Enthusiasm is not a substitute for a baseline metabolic panel.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For MK-677 for muscle gains: what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Used for PCOS pages comparing metabolic and weight-management approaches.
PubMed
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity
Supports PCOS, obesity, and hormonal-regulation context.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
MK-677 for muscle gains: what the evidence actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
MK-677 (ibutamoren) is an orally bioavailable ghrelin receptor agonist that stimulates GH and IGF-1 secretion.
FormBlends verdict
MK-677 (ibutamoren) is an orally bioavailable ghrelin receptor agonist that stimulates GH and IGF-1 secretion. Clinical studies have documented improvements in REM sleep architecture and appetite stimulation as primary pharmacodynamic effects. Chronic use raises IGF-1, which warrants baseline and follow-up lab monitoring, particularly for fasting glucose and insulin sensitivity, neither of which this creator discusses.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- MK-677 (ibutamoren) is an orally bioavailable ghrelin receptor agonist that stimulates GH and IGF-1 secretion. Clinical studies have documented improvements in REM sleep architecture and appetite stimulation as primary pharmacodynamic effects. Chronic use raises IGF-1, which warrants baseline and follow-up lab monitoring, particularly for fasting glucose and insulin sensitivity, neither of which this creator discusses.
- Copinschi et al. (1997) found MK-677 increased REM sleep duration in controlled trials, so the sleep rationale is not without basis.
- MK-677 activates ghrelin receptors, and ghrelin is the primary hunger-stimulating hormone. Appetite increase is one of its most consistent documented effects.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Copinschi et al. (1997) found MK-677 increased REM sleep duration in controlled trials, so the sleep rationale is not without basis.
- MK-677 activates ghrelin receptors, and ghrelin is the primary hunger-stimulating hormone. Appetite increase is one of its most consistent documented effects.
- Nass et al. (2008) reported edema and insulin resistance signals in a two-year MK-677 trial. The creator mentions bloating but never addresses blood glucose.
- Night dosing to reduce daytime hunger is a common user strategy with no controlled evidence behind it. It shifts when hunger peaks, not necessarily total caloric drive.
- MK-677 is not FDA-approved and cannot be legally sold as a supplement. Legitimate access in the U.S. requires a licensed provider and a prescription through regulated compounding channels.
- IGF-1 elevation from MK-677 is measurable within days, not weeks. A four-week run without baseline labs is not a low-stakes experiment.
- Self-sourcing gray-market compounds introduces contamination and dosing accuracy risks that are entirely absent from this video's framing.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
liftsbyfahd · TikTok creator
22.8K views on this video
DAY 1 BOYS LETS RUN IT UP #gym #fitness #viral #mk677 #gymtok
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by liftsbyfahd, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.